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ABSTRACT
Background: Currently there is major lack of agreement on the diagnostic and therapeutic management of
patients with idiopathic pulmonary fibrosis (IPF) and lung cancer. Our aim was to identify variations in
diagnostic and management strategies across different institutions and provide rationale for a consensus
statement on this issue.
Methods: This was a joint-survey by European Respiratory Society (ERS) Assemblies 8, 11 and 12. The
survey consisted of 25 questions.
Results: Four hundred and ninety-four (n=494) physicians from 68 different countries and five continents
responded to the survey. Ninety-four per cent of participants were pulmonologists, 1.8% thoracic surgeons
and 1.9% oncologists; 97.7% were involved in multidisciplinary team approaches on diagnosis and
management. Regular low-dose high-resolution computed tomography (HRCT) scan was used by 49.5% of
the respondents to screen for lung cancer in IPF. Positron emission tomography (PET) scan and
endobronchial ultrasound (EBUS) is performed by 60% and 88% to diagnose nodular lesions with
mediastinal lymphadenopathy in patients with advanced and mild IPF, respectively. Eighty-three per cent
of respondents continue anti-fibrotics following lung cancer diagnosis; safety precautions during surgical
interventions including low tidal volume are applied by 67%. Stereotactic radiotherapy is used to treat
patients with advanced IPF (diffusing capacity of the lung for carbon monoxide (DLCO) <35%) and
otherwise operable nonsmall cell lung cancer (NSCLC) by 54% of respondents and doublet platinum
regimens and immunotherapy for metastatic disease by 25% and 31.9%, respectively. Almost all
participants (93%) replied that a consensus statement for the management of these patients is highly
warranted.
Conclusion: The diagnosis and management of IPF-lung cancer (LC) is heterogeneous with most
respondents calling for a consensus statement.
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ORIGINAL ARTICLE
LUNG CANCER AND IPF
Introduction
Idiopathic pulmonary fibrosis (IPF) is a debilitating fibrotic lung disease of unknown origin and
pathogenesis that is steadily increasing in both incidence and mortality (40 000 patients die from IPF each
year in the USA, the same as breast cancer). Until recently, there was no effective therapy for IPF, except
lung transplantation [1]. Although there are two compounds licensed for the treatment of IPF that have
been shown to reduce disease progression with encouraging safety and efficacy data [2, 3], neither
compound has been tested prospectively in IPF patients with major comorbidities such as lung cancer [4].
Recent epidemiological evidence suggests that 3–22% of patients with IPF develop lung cancer with an
increasing risk during disease course of up to 50% and a nearly five-fold increased risk compared to the
general population [5–8].This has a negative impact on patients’ survival and quality of life [9–12], and
most treatments for lung cancer are associated with a high morbidity and mortality in patients with IPF.
Additionally, IPF and lung cancer have striking pathogenetic commonalities including microsatellite
instability, epigenetic alterations, telomere attrition and impaired cellular bioenergetics [4, 13–16].
Unfortunately, there is considerable lack of agreement on the diagnostic and therapeutic management of
these patients [17]. Current American Thoracic Society, European Respiratory Society, Japanese
Respiratory Society and Latin American Thoracic Society (ATS/ERS/JRS/ALAT) guidelines (2018) [1] do
not address this crucial issue, and there are no large randomised controlled trial data on IPF-lung cancer
(LC) available [13].
We hypothesised that clinical approaches to the diagnosis and management of IPF-LC might vary
substantially across different institutions internationally, with documentation of this allowing research
questions to be prioritised. Thus, we conducted an international survey, called the DIAMORFOSIS
(DIAgnosis and Management Of lung canceR and FibrOSIS) survey, to identify variations in diagnostic
and management strategies across different institutions, raise awareness on the coexistence of these two
diseases, provide rationale for a consensus statement on this issue and fuel future research and clinical
study design. Some of the results have been previously published in the form of an abstract.
Materials and methods
Questionnaire and participating physicians
To identify all items to be included in the survey, we performed literature research on diagnosis, treatment
and management of IPF-LC (www.ncbi.nlm.nih.gov/pubmed and www.scholar.google.com) by setting
specific key words as indicated in supplementary file 1. Following this, an expert panel was formulated,
encompassing respiratory physicians and oncologists from European Respiratory Society (ERS) Assemblies
8, 11 and 12 (Thoracic Surgery and Lung Transplantation, Thoracic Oncology and Interstitial Lung
Diseases, respectively). Members of the expert panel were required to have experience in the diagnosis and
management of IPF and lung cancer and work in reference centres of excellence for interstitial lung
diseases (ILDs) and Thoracic Oncology to participate in an e-mail-based discussion to structure the
survey. The final version of the questionnaire comprised 25 questions divided into five categories:
1) Participants, 2) General knowledge, 3) Diagnosis, 4) Management and 5) Future perspectives
(supplementary file 2). The questionnaire was distributed through two different platforms, Google and
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SurveyMonkey. The Google platform was used by the ERS to disseminate the questionnaire through
members of the ERS Assemblies 8, 11 and 12. The SurveyMonkey platform was used to disseminate the
survey to other participants identified (through an internet search) to have a particular interest in ILDs
and Thoracic Oncology. Results were homogenised into an Excel spreadsheet, and duplicate participants
were excluded from the analysis. In both cases, participants were invited to participate through an e-mail
link. The questionnaire was available from March 2019 to September 2019. Details of the questionnaire
can be found in supplementary file 3.
Statistical analysis
All questions of the survey involved categorical answers, and absolute and relative frequencies were
calculated. Due to the exploratory nature of this survey and the small number of participants in country
subgroups, no comparisons between participants from different countries or continents were performed,
and thus no p-values were calculated. All frequencies were treated descriptively.
Results
Participants
Overall, 494 physicians from 68 different countries and five continents responded to the survey with a
response rate of 28% (494 out of 1758) (figure 1). Ninety-four per cent of participants were
pulmonologists, 1.8% thoracic surgeons and 1.9% thoracic oncologists; 67% and 21.6% were from
University and non-University hospitals, respectively, and 51.5% were treating >20 patients with IPF per
year. The majority of participants (63.2%) stated a clinical experience of >10 years as specialists (figure 2).
General information
Lung cancer incidence was between 5 and 10% of total IPF cases according to 45.3% of participants, while
a big discrepancy between participants stating an incidence of 1–5% (30.8%) and those stating an
incidence >20% (21.8%) was noted. Both the incidence and the type of non-lung cancer cases were
unknown to a large proportion of the participants (38.8% and 45.6%, respectively). Prostate, colon and
breast cancer were reported as the most common types of non-lung cancer cases in patients with IPF by
19.3%, 14.2% and 3.9%, respectively (data not shown). The majority of the participants (54%) declared
that lower lobes are the most frequent anatomical location of the lung cancer lesions in their cohort of
patients, while upper lobes were the most frequent location in 18.3%. According to the majority of
participants (85.2%) nonsmall cell lung cancer (NSCLC) was the most common histological type of lung
cancer in patients with IPF, with adenocarcinoma being the most frequent (58.6%), followed by squamous
(26.6%) and small cell lung cancer (SCLC) (12.3%) (figure 3).
Diagnostic approaches
Annual low-dose high-resolution computed tomography (HRCT) represented the most frequent screening
modality for lung cancer in patients with IPF in 78.7% of participants, followed by no screening at all in
10a)




































































































































































































































































































































































FIGURE 1 Country (a) and continent (b) of origin of participants.
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17.6% of participants. Positron emission tomography (PET) CT scan followed by endobronchial
ultrasound (EBUS), in case of PET positivity, was applied as a diagnostic approach in the majority of
participants in patients with 20 mm central nodular lesions and IPF of either mild-to-moderate (forced
vital capacity (FVC) >50%, diffusing capacity of the lung for carbon monoxide (DLCO) >35%) or severe
(FVC <50%, DLCO <35%) functional impairment (87.9% and 59.7%, respectively); yet this approach was
performed more often in mild-to-moderate disease than in severe disease. Median latency time between
diagnosis of IPF and lung cancer was >12 months, as stated by 57% of respondents, while it was unknown
in 27.7% (figure 4).
Management procedures
Multidisciplinary approaches for the management of patients with IPF-LC were applied by 78.2% of
respondents. The majority of participants (83.8%) continued treatment with anti-fibrotics when a patient
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What is your medical specialty? What is your hospital setting?
How many patients with IPF do you treat per year? How many years of experience










































































































































FIGURE 2 Clinical experience of participants.
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with IPF was diagnosed with lung cancer. Major disagreement was noted in whether moderate or severe
IPF is an absolute contraindication for radiotherapy or chemotherapy in patients with locally advanced
NSCLC, with 40.2% of participants disagreeing, 37.2% agreeing and 20.2% stating uncertainty (figure 5).
In a patient with IPF of mild-to-moderate functional impairment (FVC >50%, DLCO >35%) diagnosed
with otherwise operable NSCLC (tumour, node, metastasis (TNM) stage I–II), surgery, stereotactic
radiotherapy (depending on the cancer stage) and continuation of anti-fibrotics were the three most
frequent management approaches in 78.2%, 40.5% and 40% of the participants, respectively. On the other
hand in a patient with advanced IPF (FVC <50%, DLCO <35%) and otherwise operable NSCLC (TNM
stage I–II) the three most frequent management strategies were stereotactic radiotherapy, continuation of
anti-fibrotics and palliative care in 54.1%, 37.6% and 30.6%, respectively, while 1 in 5 (21.4%) participants
performed surgical interventions. In the case of both advanced IPF and lung cancer (TNM stage IV) the
majority of participants (69%) applied palliative care, followed by anti-fibrotics (37%), immune checkpoint
inhibitors (31.9%) and targeted therapy (35.4%). Doublet platinum regimens and immunotherapy for
metastatic disease were chosen by 25% and 31.9%, respectively (figure 6).
50
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What is the most common anatomical location for
lung cancer in patients with IPF?
What is the most common histologic subtype of
lung cancer in patients with IPF?
What is the incidence of lung cancer
in patients with IPF?
What percentage of patients with IPF present with
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FIGURE 3 General information on patients. IPF: idiopathic pulmonary fibrosis; NSCLC: nonsmall cell lung cancer; ADC: adenocarcinoma; SQLC:
squamous cell lung cancer; SCLC: small cell lung cancer.
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Regarding pre- and peri-operative safety precautions, continuation of anti-fibrotics, low tidal volume,
avoidance of high fraction of inspired oxygen and minimal surgical interventions represented the most
frequently applied approaches in 67.1%, 55.1%, 45.5% and 30.6% of participants, respectively (figure 5).
Future perspectives
Based on the vast majority of participants (92.9%), a consensus statement for the diagnosis and
management of patients with IPF-LC is mandatory for improved, homogeneous and standardised
approaches. Further comments of particular interest provided by individual participants in the context of
an open question were: the need for a global registry, the role of immune checkpoint inhibitors and
targeted treatments, future research studies and clinical trials.
Discussion
Currently there is a major need for a consensus view of diagnostic and management strategies in patients
with concomitant IPF and lung cancer. Our findings highlighted the variability in management
approaches of patients with concomitant IPF and lung cancer, as participants reached consensus in only
five items of the questionnaire. Our study demonstrated that there is a pressing need for increased
awareness as well, given that in our survey only 28% of physicians responded to the invitation. To this
30
What is the median latency time (months) between
IPF and lung cancer diagnosis in your experience?
What would be your next diagnostic step in a patient with 
mild-to-moderate IPF (DLCO>35%, FVC>50%) with a central 
nodular lesion of 20mm and mediastinal lymphadenopathy?
What would be your next diagnostic step in a patient with 
severe IPF (DLCO<35%, FVC<50%) with a central nodular 
lesion of 20mm and mediastinal lymphadenopathy?
What diagnostic modality do you use to screen patients 


















































































































































Median latency time months
FIGURE 4 Diagnostic approaches. IPF: idiopathic pulmonary fibrosis; HRCT: high-resolution computed tomography; CXR: chest radiograph; DLCO:
diffusing capacity of the lung for carbon monoxide; FVC: forced vital capacity; PET-CT: positron emission tomography/computed tomography;
EBUS-TBNB: endobronchial ultrasound/transbronchial needle biopsy; SLB (VATS): surgical lung biopsy (video-assisted thoracoscopic surgery).
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end, areas of uncertainty and disagreement between physicians across the world need to be identified and
addressed. It is a common misconception that consensus statements need a level of data not present in
this field. Our survey included a significant number of participants (n=494) from six continents and
identified key areas of uncertainty, as indicated by major heterogeneity in diagnostic and management
practices. It also highlighted a general agreement among all participants to generate a consensus statement
for harmonised approaches that will fuel clinical trials and further research.
The results of our survey could be summarised in two categories based on whether agreement between
participants reached consensus, defined as per cent agreement between respondents above 75%.
Interestingly, our survey revealed that participants reached consensus in only five items of the
questionnaire, including: 1) use of multidisciplinary discussion approaches (78.2%); 2) continuation of
anti-fibrotic treatment in patients with IPF diagnosed with lung cancer (83.8%); 3) application of PET-CT
scan and EBUS for the diagnosis of a central nodular lesion of 20 mm in patients with mild-to-moderate
IPF and mediastinal lymphadenopathy (87.9%); 4) surgical lung interventions in mild-to-moderate IPF
cases (78.2%); and 5) need for a consensus statement (92.9%). This observation confirms our initial
hypothesis regarding major variability in management approaches, reflecting areas of major uncertainty
and highlighting the need for a consensus statement. Regarding areas of major variability and uncertainty































How often do you involve a multidisciplinary team on the
management of patients with IPF and lung cancer?
Do you continue anti-fibrotic treatment (pirfenidone or nintedanib) 
when a patient is diagnosed with lung cancer (any stage)?
Do you agree with the following statement: moderate-to-severe IPF 
is an absolute contraindication to radiotherapy or chemotherapy in 
locally advanced NSCLC?
Which safety precautions do you apply to patients with IPF and 






















































































FIGURE 5 Management procedures. IPF: idiopathic pulmonary fibrosis; NSCLC: nonsmall cell lung cancer.
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low-dose HRCT on a regular (annual) basis; 2) optimal selection of patients for surgical lung
interventions, chemotherapy and radiotherapy; and 3) the role of anti-fibrotics on prevention of lung
cancer, treatment of lung cancer and reduction of acute exacerbations of IPF post-operatively.
Based on the latest US Preventive Services Task Force Recommendation Statement, all patients with IPF
should be considered as high risk for developing lung cancer, given a much higher incidence compared to
patients currently screened for lung cancer [7]. Thus, close monitoring by means of annual HRCT should
be considered mandatory as it happens with other chronic lung diseases, including COPD [18]. This has
become a more important issue with the implementation of novel anti-fibrotics leading to better disease
outcomes and survival prolongation, given a potential accumulative incidence of lung cancer. Surprisingly,
a substantial minority of participants suggested either an HRCT scan in case of additional symptoms
(29.1%) or no screening at all (17.6%). Though it is evident in our clinical practice, as yet the benefit of
screening patients with IPF by means of HRCT on a regular basis has not been proven in the context of a





How would you treat a patient with mild-to-moderate IPF 
(DLCO>35%, FVC>50%) and otherwise operable NSCLC nodule (TNM 
stage I–II)?
How would you treat a patient with mild-to-moderate IPF 
(DLCO>35%, FVC>50%) and otherwise operable NSCLC nodule
(TNM stage I–II)?
Do you consider any of the following treatments for advanced stage 
NSCLC an absolute contraindication in moderate-to-severe IPF 
(more than one answer possible)?
How would you treat a patient with advanced IPF 





























































































































































































































































































































































































































































FIGURE 6 Management procedures (continued). IPF: idiopathic pulmonary fibrosis; DLCO: diffusing capacity of the lung for carbon monoxide; FVC:
forced vital capacity; TNM: tumour, node, metastasis; NSCLC: nonsmall cell lung cancer.
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Optimal selection of patients with IPF-LC for diagnostic and therapeutic interventions represents an ongoing
debate. In our survey, participants agreed that patients with mild-to-moderate IPF and otherwise operable
lung cancer lesions should be subjected either to bronchoscopic (87.9%) or lung resection procedures
(78.2%) for diagnostic and therapeutic purposes, respectively, because the benefits outweigh the risks. On the
contrary, agreement rates were substantially decreased in severe IPF cases with operable lung cancer lesions,
where interventional procedures were suggested by 59.6% and 21.4% of respondents, for diagnosis and
treatment, respectively, due to potential severe post-operative complications. Retrospective series have shown
that patients with IPF exhibit higher risk for post-operative acute respiratory events than non-IPF patients
[19], especially acute exacerbation [20]. Experts suggest that reduction of the duration of one-lung
ventilation, videothoracoscopic surgery under spontaneous ventilation in selected patients, minimal tissue
manipulation, low tidal volume ventilation strategies and avoidance of high inspiratory oxygen fraction (FIO2)
perioperatively may exert prophylactic effects [21, 22]. In a large retrospective Japanese cohort of 1763
patients with different forms of ILDs and lung resection for lung cancer, duration and extent of surgical
procedures, as well as peri-operative fraction of inspired oxygen and fluid intake, were independent risk
factors of acute exacerbations [23]. To this end, a preoperative multidisciplinary evaluation should also
include thoracic surgeons and anaesthesiologists in order to increase their awareness of peri- and
post-operative complications of aggressive ventilation and excessive tissue manipulation, especially in patients
with severely impaired lung compliance, as those with IPF. We believe that surgical lung interventions
should be performed in highly selected cases based on reliable prognosticators such as functional and general
performance status or composite physiological index, a multidimensional scoring system that quantifies
functional and radiological impairment [14]. The deceptive nature of functional parameters in the presence
of emphysema needs to be considered in this context.
Currently there are scarce data on the optimal chemotherapeutic regimen in patients with IPF-LC. In our
survey only 1 in 4 participants would implement doublet platinum regimens in patients with IPF and
metastatic lung cancer. Studies have shown increased pulmonary toxicity in patients with interstitial lung
disease who were treated with either docetaxel or pemetrexed as well as etoposide-based regimens [24, 25].
So far, only carboplatin has shown moderate therapeutic effects with minimal toxicity [26]. A randomised
controlled study ( J-SONIC) investigating the efficacy of carboplatin plus nab-paclitaxel with or without
nintedanib in patients with NSCLC associated with IPF is currently ongoing in Japan, and results are
greatly anticipated. In the context of similar disease pathophysiology between lung cancer and IPF [15],
studies investigating the effects of new immunomodulatory agents, including programmed death-ligand
(PD-L) 1 inhibitors, would be of significant interest for a selective number of cases, i.e. those with
upregulated PD1/PD-L1 axis [27]; yet caution should be applied considering cases of interstitial
pneumonia potentially associated with nivolumab treatment [28, 29]. Molecular testing for epidermal
growth factor-receptor, KRAS and EML4-ALK mutations could also be performed for targeted treatments,
as indicated by some of the participants.
With regards to radiotherapy scarce data has shown deleterious effects on patients with established lung
fibrosis [9] suggesting that radiotherapy involving the lung, including stereotactic radiotherapy, should be
generally avoided, unless life-threatening situations arise. Besides radiation pneumonitis, mortality after
radiofrequency ablation was mainly due to pneumothoraces [30]. This is important considering that 40%
of patients with IPF present with concomitant emphysema [31]. Despite these data, stereotactic
radiotherapy was the predominant therapeutic intervention for severe IPF cases with operable IPF-LC
lesions, as indicated by 54.1% of participants. Proton beam therapy has recently shown promising results
in terms of safety in a small series of patients with IPF and lung cancer; yet the study was underpowered
and retrospective [32]. Further studies are needed on the safety and efficacy of chemotherapeutic and
immunomodulatory regimens as well as modern irradiation techniques including proton beam therapy.
Another challenge of the real-world clinical practice is whether anti-fibrotic agents can be combined or
even synergise with chemotherapy or radiotherapy. Nintedanib has been developed as an antiangiogenic
molecule and has been approved for treatment of non-squamous NSCLC [33] in combination with
docetaxel-based second-line therapy. Retrospective data suggested a beneficial effect of preoperative
pirfenidone on the incidence of post-operative acute exacerbations in patients with adenocarcinoma and
IPF [34]. In agreement with the majority of respondents, we suggest that anti-fibrotic agents should not be
discontinued during diagnostic or therapeutic workup of lung cancer, as benefits seem to outweigh the
risk for unfavourable outcomes. Whether nintedanib monotherapy as cancer treatment represents a
plausible strategy needs to be addressed in the context of clinical trials. Final decision should be based on
multidisciplinary discussion including oncologists and on a case-by-case basis considering severity of IPF,
TNM stage of lung cancer, performance status of the patient and patient’s preferences.
Early implementation of palliative care may be appropriate and possibly improve patients’ quality of life
despite no effect on survival [35]. In agreement with current literature showing encouraging efficacy data
https://doi.org/10.1183/23120541.00529-2020 9
LUNG CANCER AND IPF | A. TZOUVELEKIS ET AL.
in both the field of oncology [36] and lung fibrosis [37–39], the majority of participants (69.1%) suggested
palliative care as a therapeutic option, particularly in advanced cases of IPF-LC. This statement also
supports the latest views that palliative care should be offered early to all patients with IPF. Larger studies
using validated outcome measures are sorely needed to assess the effects of palliative care interventions on
symptoms, quality of life and survival of patients with IPF-LC irrespective of disease severity.
Despite its important attributes, our survey exhibits several limitations that should be addressed cautiously.
Although the study was powered by the participation of almost 500 respondents across the world, results
may reflect the personal opinions of physicians and may not represent objective assessment of everyday
clinical practices. Additionally, there was an over-representation of pulmonologists (94%) while thoracic
oncologists, radio-oncologists and surgeons were under-represented. Heterogeneity in answers may also
mirror differences in access to treatments (targeted therapies, immune checkpoint inhibitors) and diagnostic
modalities (i.e. PET-CT scan, EBUS), which may be limited in some countries due to regulatory issues.
Moreover, our main aim was to survey international practices on diagnosis and treatment of patients with
IPF-LC, and thus our study is unable to provide accurate epidemiological data. This needs to be addressed in
the context of global registries, either retrospectively or prospectively. Such registries are more timely than
ever, given that patients with IPF live longer and the incidence of lung cancer might increase. Finally, it was
impossible for our survey to cover all areas of uncertainty in the field of IPF-LC. In particular, data on the
impact of combined pulmonary fibrosis and emphysema (CPFE) and interstitial lung abnormalities (ILAs)
on management decisions is sorely needed. Another major limitation that needs to be addressed is the lack
of information on patient preferences regarding diagnostic and therapeutic interventions considering the fact
that we are dealing with a very vulnerable population of patients. On the other hand, our questionnaire was
anonymous and therefore answers provided are expected to be less biased.
Conclusion
In conclusion, our survey revealed major heterogeneity in diagnostic and management strategies in
patients with IPF-LC, mainly arising from lack of knowledge and uncertainty in key areas of this field. ILD
practitioners and oncologists almost unanimously agreed that in this poorly defined area a consensus
statement for harmonised and standardised approaches is eagerly anticipated. This will fuel future trials
and research studies with major impact on patients’ survival and quality of life.
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